Loading
Loading
Research Overview
Long-acting amylin analogue; activates amylin receptors (AMY1–3) in the brainstem and hypothalamus to reduce food intake, slow gastric emptying, and suppress glucagon. Combined with semaglutide as 'CagriSema' in clinical trials.
Cagrilintide is a fatty acid-acylated amylin analogue designed to extend the plasma half-life of amylin receptor agonist activity. Preclinical research has examined its effects on satiety-related neural circuits, gastric emptying rate, and circulating metabolic markers in animal model systems.
The combination of cagrilintide with semaglutide, studied as CagriSema, has been an active area of preclinical investigation. Researchers have used animal models to examine whether amylin and GLP-1 receptor co-activation produces additive or synergistic effects on body weight, food intake, and metabolic parameters.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, cagrilintide (long-acting amylin analogue) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Cagrilintide (Long-Acting Amylin Analogue) research is most relevant to protocols examining:
Amylin receptor pathway research and brainstem satiety signalling
CagriSema combination trial follow-up research
Studies comparing amylin-axis vs GLP-1-axis appetite suppression
Researchers investigating complementary mechanisms beyond GLP-1 monotherapy
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~7–8 days). Review data, confirm baseline recovery before any repeat protocol.
Long-acting amylin analogue; activates amylin receptors (AMY1–3) in the brainstem and hypothalamus to reduce food intake, slow gastric emptying, and suppress glucagon. Combined with semaglutide as 'CagriSema' in clinical trials.
| Parameter | Value |
|---|---|
| Dose range | 0.16–4.5 mg/week (trial range) |
| Schedule | Once weekly |
| Route | Subcutaneous |
| Half-life | ~7–8 days |
Available from Capital Peptides
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.